Y Intercept Hong Kong Ltd Makes New $657,000 Investment in Cellebrite DI Ltd. $CLBT

Y Intercept Hong Kong Ltd acquired a new position in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 41,034 shares of the company’s stock, valued at approximately $657,000.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Voss Capital LP increased its stake in Cellebrite DI by 18.6% during the 1st quarter. Voss Capital LP now owns 3,843,602 shares of the company’s stock worth $74,681,000 after acquiring an additional 603,602 shares during the period. Invesco Ltd. increased its stake in Cellebrite DI by 122.1% during the 1st quarter. Invesco Ltd. now owns 3,296,079 shares of the company’s stock worth $64,043,000 after acquiring an additional 1,811,757 shares during the period. T. Rowe Price Investment Management Inc. bought a new position in Cellebrite DI during the 1st quarter worth $60,939,000. Phoenix Financial Ltd. increased its stake in Cellebrite DI by 153.5% during the 2nd quarter. Phoenix Financial Ltd. now owns 2,014,617 shares of the company’s stock worth $32,232,000 after acquiring an additional 1,219,958 shares during the period. Finally, Bank of New York Mellon Corp bought a new position in Cellebrite DI during the 1st quarter worth $22,428,000. Institutional investors own 45.88% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have commented on CLBT shares. Needham & Company LLC lowered their price objective on Cellebrite DI from $24.00 to $18.00 and set a “buy” rating on the stock in a research note on Thursday, August 14th. Weiss Ratings restated a “sell (d+)” rating on shares of Cellebrite DI in a research note on Wednesday, October 8th. Wall Street Zen upgraded Cellebrite DI from a “hold” rating to a “buy” rating in a research note on Friday, September 26th. Lake Street Capital decreased their price target on Cellebrite DI from $24.00 to $22.00 and set a “buy” rating on the stock in a research note on Friday, August 15th. Finally, JPMorgan Chase & Co. lifted their price target on Cellebrite DI from $20.00 to $23.00 and gave the company an “overweight” rating in a research note on Wednesday, September 24th. Four equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $21.75.

Cellebrite DI Stock Up 0.9%

Shares of CLBT stock opened at $16.05 on Thursday. The firm has a market capitalization of $3.84 billion, a P/E ratio of -21.12, a P/E/G ratio of 3.16 and a beta of 1.28. Cellebrite DI Ltd. has a twelve month low of $13.10 and a twelve month high of $26.30. The stock’s fifty day simple moving average is $17.81 and its 200 day simple moving average is $16.81.

Cellebrite DI (NASDAQ:CLBT) last issued its quarterly earnings data on Thursday, August 14th. The company reported $0.12 earnings per share for the quarter, topping analysts’ consensus estimates of $0.11 by $0.01. The business had revenue of $113.28 million for the quarter, compared to analyst estimates of $112.33 million. Cellebrite DI had a positive return on equity of 23.92% and a negative net margin of 34.56%.Cellebrite DI’s quarterly revenue was up 18.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.10 EPS. Cellebrite DI has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, equities research analysts expect that Cellebrite DI Ltd. will post 0.3 EPS for the current fiscal year.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.